- Home
- JYD vs RLMD Comparison
JYD vs RLMD Comparison
Compare JYD & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYD
- RLMD
- Stock Information
- Founded
- JYD 2001
- RLMD 2004
- Country
- JYD China
- RLMD United States
- Employees
- JYD N/A
- RLMD N/A
- Industry
- JYD Oil Refining/Marketing
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- JYD Consumer Discretionary
- RLMD Health Care
- Exchange
- JYD Nasdaq
- RLMD Nasdaq
- Market Cap
- JYD 17.8M
- RLMD 20.3M
- IPO Year
- JYD 2023
- RLMD N/A
- Fundamental
- Price
- JYD $0.19
- RLMD $0.62
- Analyst Decision
- JYD
- RLMD Buy
- Analyst Count
- JYD 0
- RLMD 3
- Target Price
- JYD N/A
- RLMD $5.00
- AVG Volume (30 Days)
- JYD 1.6M
- RLMD 206.1K
- Earning Date
- JYD 08-12-2025
- RLMD 08-07-2025
- Dividend Yield
- JYD N/A
- RLMD N/A
- EPS Growth
- JYD N/A
- RLMD N/A
- EPS
- JYD N/A
- RLMD N/A
- Revenue
- JYD $77,444,271.00
- RLMD N/A
- Revenue This Year
- JYD N/A
- RLMD N/A
- Revenue Next Year
- JYD N/A
- RLMD N/A
- P/E Ratio
- JYD N/A
- RLMD N/A
- Revenue Growth
- JYD 13.54
- RLMD N/A
- 52 Week Low
- JYD $0.09
- RLMD $0.24
- 52 Week High
- JYD $8.00
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- JYD 39.83
- RLMD 48.62
- Support Level
- JYD $0.22
- RLMD $0.60
- Resistance Level
- JYD $0.25
- RLMD $0.67
- Average True Range (ATR)
- JYD 0.02
- RLMD 0.06
- MACD
- JYD 0.01
- RLMD 0.00
- Stochastic Oscillator
- JYD 19.61
- RLMD 34.30
About JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, supply chain management, and other value-added services.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.